Atrial fibrillation and myocardial infarction – in constant need for new data

Abstract

Get full access to this article

View all access options for this article.

References

Jernberg

Johanson

Held

, et al. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 2011; 305: 1677–1684.

Gasior

Pres

Wojakowski

, et al. Causes of hospitalization and prognosis in patients with cardiovascular diseases. Secular trends in the years 2006–2014 according to the SILesian CARDiovascular database. Pol Arch Med Wewn 2016; 126: 754–762.

Mozaffarian

Benjamin

, et al. Heart disease and stroke statistics—2015 update: A report from the American Heart Association. Circulation 2015; 131: e29–e322.

Kirchhof

Benussi

Kotecha

, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893–2962.

Schmitt

Duray

Gersh

, et al. Atrial fibrillation in acute myocardial infarction: A systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009; 30: 1038–1045.

Violi

Soliman

Pignatelli

, et al. Atrial fibrillation and myocardial infarction: A systematic review and appraisal of pathophysiologic mechanisms. J Am Heart Assoc 2016; 5: e003347–e003347.

Forcadell

Vila-Córcoles

de Diego

, et al. Incidence and mortality of myocardial infarction among Catalonian older adults with and without underlying risk conditions: The CAPAMIS study. Eur J Prev Cardiol 2018; 25: 1822–1830.

Ruddox

Sandven

Munkhaugen

, et al. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis. Eur J Prev Cardiol 2017; 24: 1555–1566.

Ibanez

James

Agewall

, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39: 119–177.

10.

Jortveit J, Pripp AH, Langørgen J, Halvorsen S. Poor adherence to guideline recommendations among patients with atrial fibrillation and acute myocardial infarction. Eur J Prev Cardiol. 2019; 26: 1373–1382.

11.

Gierlotka

Gasior

Wilczek

, et al. Temporal trends in the treatment and outcomes of patients With non-ST-segment elevation myocardial infarction in Poland from 2004–2010 (from the Polish Registry of Acute Coronary Syndromes). Am J Cardiol 2012; 109: 779–786.

12.

Szummer

Wallentin

Lindhagen

, et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: Experiences from the SWEDEHEART registry 1995–2014. Eur Heart J 2017; 38: 3056–3065.

13.

Stenestrand

Lindback

Wallentin

, et al. Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: A prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Circulation 2005; 112: 3225–3231.

14.

Eikelboom

Connolly

Bosch

, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N J Med 2017; 377: 1319–1330.

15.

Darmon

Bhatt

Elbez

, et al. External applicability of the COMPASS trial: An analysis of the reduction of atherothrombosis for continued health (REACH) registry. Eur Heart J 2018; 39: 750–757a.

16.

Cannon

Bhatt

Oldgren

, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017; 377: 1513–1524.

17.

Valgimigli

Bueno

Byrne

, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg 2018; 53: 34–78.